151 related articles for article (PubMed ID: 3456283)
1. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.
Schrøder H; Clausen N; Ostergaard E; Pressler T
Cancer Chemother Pharmacol; 1986; 16(2):190-3. PubMed ID: 3456283
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.
Schrøder H; Fogh K
Cancer Chemother Pharmacol; 1988; 21(2):145-9. PubMed ID: 2450690
[TBL] [Abstract][Full Text] [Related]
3. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia.
Pinkerton CR; Welshman SG; Kelly JG; Shanks RG; Bridges JM
Cancer Chemother Pharmacol; 1982 Dec; 10(1):36-9. PubMed ID: 6961972
[TBL] [Abstract][Full Text] [Related]
5. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes.
Schmiegelow K; Schrøder H; Pulczynska MK; Hejl M
Cancer Chemother Pharmacol; 1989; 25(1):65-9. PubMed ID: 2591003
[TBL] [Abstract][Full Text] [Related]
6. In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes.
Schrøder H
Dan Med Bull; 1990 Feb; 37(1):22-40. PubMed ID: 2178886
[TBL] [Abstract][Full Text] [Related]
7. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia.
Beach BJ; Woods WG; Howell SB
Am J Pediatr Hematol Oncol; 1981; 3(2):115-9. PubMed ID: 6975580
[TBL] [Abstract][Full Text] [Related]
8. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.
Schrøder H; Fogh K; Herlin T
Cancer Chemother Pharmacol; 1988; 21(2):150-5. PubMed ID: 2450691
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate in neutrophils in children with acute lymphoblastic leukemia.
Schrøder H
Cancer Chemother Pharmacol; 1987; 19(4):339-42. PubMed ID: 3474084
[TBL] [Abstract][Full Text] [Related]
10. Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia.
Evans WE; Stewart CF; Hutson PR; Cairnes DA; Bowman WP; Yee GC; Crom WR
Drug Intell Clin Pharm; 1982 Nov; 16(11):839-42. PubMed ID: 6959800
[TBL] [Abstract][Full Text] [Related]
11. Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate.
Skoglund KA; Söderhäll S; Beck O; Peterson C; Wennberg M; Hayder S; Björk O
Med Pediatr Oncol; 1994; 22(3):187-93. PubMed ID: 8272008
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.
Sonneveld P; Schultz FW; Nooter K; Hählen K
Cancer Chemother Pharmacol; 1986; 18(2):111-6. PubMed ID: 3791556
[TBL] [Abstract][Full Text] [Related]
14. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children.
Borsi JD; Moe PJ
Cancer; 1987 Dec; 60(12):3020-4. PubMed ID: 3479231
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte concentrations of metabolites or cumulative doses of 6-mercaptopurine and methotrexate do not predict liver changes in children treated for acute lymphoblastic leukemia.
Halonen P; Mattila J; Mäkipernaa A; Ruuska T; Schmiegelow K
Pediatr Blood Cancer; 2006 Jun; 46(7):762-6. PubMed ID: 16395677
[TBL] [Abstract][Full Text] [Related]
17. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Moe PJ
Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate.
Schalhorn A; Sauer H; Wilmanns W; Stupp-Poutot G
Cancer Chemother Pharmacol; 1982; 9(1):65-9. PubMed ID: 7139854
[TBL] [Abstract][Full Text] [Related]
19. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate absorption in children with acute lymphoblastic leukemia.
Craft AW; Rankin A; Aherne W
Cancer Treat Rep; 1981; 65 Suppl 1():77-81. PubMed ID: 6948609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
